Thalidomide ban to be lifted in the USBMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7110.697e (Published 20 September 1997) Cite this as: BMJ 1997;315:697
- Terri Rutter
A scientific advisory committee to the Food and Drug Administration has recommended that thalidomide, which has never been licensed in the United States, should be allowed to be used to treat serious inflammatory conditions associated with leprosy.
Once approved, the drug could also be prescribed, under certain restrictions, to treat other diseases, including some forms of cancer, lupus, chronic host-graft disease, and some complications due to …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial